Regorafenib Plus Vincristine and Irinotecan in Pediatric Patients With Recurrent/Refractory Solid Tumors: An Innovative Therapies for Children With Cancer Study.

Michela Casanova,Francisco Bautista,Quentin Campbell Hewson,Guy Makin,Lynley V Marshall,Arnauld C Verschuur,Adela Cañete Nieto,Nadege Corradini,Bart A Ploeger,Barbara J Brennan,Udo Mueller, Hong Zebger Gong, John W Chung,Birgit Geoerger

Clinical cancer research : an official journal of the American Association for Cancer Research（2023）

引用 0|浏览9

暂无评分

摘要

Regorafenib can be combined sequentially with standard dose VI in pediatric patients with relapsed/refractory solid tumors with appropriate dose modifications. Clinical activity was observed in patients with RMS and EWS (clinicaltrials.gov NCT02085148).

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要